ABCD Semaglutide Audit
About the ABCD nationwide semaglutide audit
This audit launched in January 2019 and followed on from the success of the ABCD nationwide audits prior to that of GLP1 receptor agonists, SGLT2 inhibitors, insulin degludec, IDegLira and FreeStyle Libre. The clinical trials with semaglutide suggest that it is more effective than the other GLP-1 receptor agonists we have had to date and it is now of interest for us to find out the extent to which the experience in clinical trials translates into the real world. There is no information from the clinical trials regarding the impact of switching from other GLP-1 receptor agonists to semaglutide - we will learn this from our audit, along with the other points of interest in the left hand column of this page - and much else. In the SUSTAIN 6 trial semaglutide seemed to have a bigger impact on cardiovascular outcomes than previously studied diabetes medications which may increase its usage in view of the consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) suggesting that agents with proven cardiovascular benefit should be used more readily in type 2 diabetes patients with established atherosclerotic cardiovascular disease. The audit is being hosted on a tool very similar to that used in the liraglutide audit, the degludec audit and the IDegLira audit so the many contributors who took part in those audits will find it particularly easy. The audit has a number of objectives.
Non ABCD members
Non ABCD members are welcome to take part in the audit and will be given access to the on-line audit tool when they register for the audit.
Analyse your own data
The tool will allow you to analyse the data of your own patients for your own local interest; at the same time the data will automatically be available for national analysis of anonymised data. A video showing how to easily analyse your data is available on the ABCD YouTube channel.
Acknowledgement of contributors
As we have done with previous audits all contributors will be acknowledged in all papers and presentations from the audit data and biggest contributors will be offered the possibility of being co-authors.
Collect data on-line or via paper forms
The semaglutide on-line audit tool is so easy to use that live data entry in clinic is a real option to be considered. Otherwise to facilitate data collection during clinics there are two paper forms which exactly match the data that can be entered into the audit tool. You can download and print these forms locally.
Audit Objectives
To see the audit objectives as they were when the audit was launched click here
Further information
Further enquiries may be made to the ABCD nationwide audits database administrator of the project, Melissa Cull.
Papers, abstracts, presentations, posters and webcasts emanating from the audit
Click here to see the output from the audit as it evolves. The names of all the contributors will be found in the presentation slides and in the published papers.
